CTOs on the Move

Powerex

www.pwrx.com

 
Powerex was established in 1988 as the wholly-owned electricity marketing subsidiary of BC Hydro – Canada’s third largest electric utility – responsible for marketing BC Hydro’s surplus electricity in the west. Today, we are a key participant in energy markets across North America, buying and supplying physical wholesale power, natural gas, ancillary services, and more recently, environmental products with an ever-expanding list of trade partners. Our portfolio of energy resources includes purchases of power and natural gas from a wide variety of energy suppliers across North America, as well as the highly reliable Canadian Entitlement energy derived from the Canada/US Columbia ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.pwrx.com
  • 173 Pavilion Lane
    Youngwood, PA USA 15697
  • Phone: 724.925.7272

Executives

Name Title Contact Details

Similar Companies

Apex Motor Sports

Apex Motor Sports is a Roseville, CA-based company in the Computers and Electronics sector.

NP Photonics, Inc.

NP Photonics, Inc. is one of the leading companies in the Computers and Electronics sector.

AVI-Tech Electronics

AVI-Tech Electronics is a San Jose, CA-based company in the Computers and Electronics sector.

Open-Silicon

Open-Silicon is a Milpitas, CA-based company in the Computers and Electronics sector.

Xceleron

Xceleron believes that AMS technology and our expertise can get life-changing products (drugs and biobased) quickly and cost-effectively to people who need them.  We work with integrity and an open mind and are driven by science and the spirit of collaboration. Founded in 1997 in York, UK, and now headquartered in Germantown, Maryland, Xceleron pioneered human microdose and microtracer techniques using AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I, and Phase II/III clinical trials. Xceleron’s experience is especially valuable because the characteristics of many contemporary small molecules (low solubility, long half-life and disproportionate human metabolites) mean that their early pharmacokinetic and metabolic characterization is critical to the cost-effectiveness of clinical development.